CASE STUDIES: ENHANCING DRUGGABILITY
Approached by a firm whose drug candidate was only 0.3% soluble, Zylö was able to increase the solubility factor almost 20-fold using its Z-pod™ technology.
Zylö’s technology has overcome the bioavailability limitations of topically applied AEA, an endocannabinoid: AEA-loaded Z-pods™ demonstrated significant reduction in lesion count and severity in a cutaneous lupus model.
TARGETING PORES OR FOLLICLES?
We can help. We are in discussions with cosmetic, OTC, and Rx companies to improve product performance through specific targeting of pores and follicles.